Can You Give Prednisone for Interstitial Lung Disease?
Yes, you can give prednisone for most types of interstitial lung disease, but the answer critically depends on the underlying cause—with systemic sclerosis-ILD being a strong contraindication and idiopathic pulmonary fibrosis showing no benefit.
Decision Algorithm Based on ILD Etiology
Systemic Autoimmune Rheumatic Disease-Associated ILD (SARD-ILD)
For most SARD-ILD (excluding SSc-ILD): Glucocorticoids are conditionally recommended as first-line treatment 1. This includes:
- Rheumatoid arthritis-ILD
- Sjögren's disease-ILD
- Inflammatory myositis-ILD
- Mixed connective tissue disease-ILD
Critical exception - Systemic Sclerosis-ILD: There is a strong recommendation AGAINST glucocorticoids as first-line treatment 1. Glucocorticoids are associated with scleroderma renal crisis, particularly at doses >15 mg/day prednisone equivalent 1. This is one of the few strong (not conditional) recommendations in the 2023 ACR/CHEST guidelines.
Rapidly Progressive ILD (RP-ILD)
For SARD with rapidly progressive disease, pulse intravenous methylprednisolone is conditionally recommended as first-line treatment 1. This represents the acute/severe presentation where high-dose steroids may be lifesaving.
Idiopathic Pulmonary Fibrosis (IPF)
Do not use corticosteroids for IPF. There is no evidence of efficacy 2, and the 2015 ATS/ERS/JRS/ALAT guideline strongly recommends against the combination of prednisone, azathioprine, and N-acetylcysteine due to harm 3. Research shows that higher corticosteroid doses improve outcomes in acute exacerbations of non-IPF-ILD but not in IPF 4.
Post-COVID-19 ILD
Methylprednisolone (0.5 mg/kg/day) has shown benefit for post-COVID organizing pneumonia, with a shorter 3-month course being noninferior to 6 months and having fewer adverse effects 5. A recent trial demonstrated functional, radiological, and physiological improvements 6.
Practical Dosing Considerations
When glucocorticoids are indicated 7:
- Initial dosing: 5-60 mg/day depending on disease severity
- Timing: Administer in the morning (before 9 AM) to minimize HPA axis suppression
- Duration: Short-term use (≤3 months) is preferred when possible 1
- Long-term use: Strongly discouraged in SSc-ILD and conditionally recommended against in other SARD-ILD with disease progression 1
- Tapering target: For anti-synthetase syndrome-ILD, aim for 12.5-15 mg/day at 6 months to balance flare and infection risk 8
Common Pitfalls to Avoid
- Using steroids in SSc-ILD: This is the most critical error—risk of renal crisis outweighs any potential benefit
- Treating IPF with corticosteroids: No evidence of benefit and potential for harm
- Long-term high-dose therapy: Even in responsive ILD types, prolonged use increases infection risk without clear benefit 1
- Ignoring preferred first-line agents: Mycophenolate is the preferred first-line therapy across most SARD-ILD types 1; steroids should be considered adjunctive or for specific situations
Real-World Context
Despite guidelines, prednisone remains commonly prescribed in RA-ILD (76.7% post-diagnosis) 9, while guideline-recommended immunosuppressants are underutilized. This suggests a gap between evidence and practice. Prioritize mycophenolate, azathioprine, rituximab, or cyclophosphamide as first-line agents 1, using glucocorticoids as short-term bridging therapy or in specific inflammatory phenotypes rather than as monotherapy.
The key is identifying the underlying cause of ILD before initiating treatment—accurate diagnosis determines whether glucocorticoids help, do nothing, or cause harm.